Libroxar

Buprenorphine, the active ingredient in Libroxar, is a partial opioid agonist / opioid antagonist combination presented as a sublingual tablet for sublingual use. It is indicated for the treatment of opioid dependence and helps manage withdrawal symptoms in adults, reducing cravings and supporting recovery.

GNH USA supplies Libroxar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for opioid dependence treatment programs. Our distribution network adheres to EU quality standards and ensures timely delivery across regions.

Libroxar (buprenorphine/naloxone) is used in opioid dependence management, acting on the opioid receptor system.

- Opioid dependence: reduces cravings and stabilises patients during recovery. - Opioid withdrawal: alleviates withdrawal symptoms and facilitates transition to maintenance therapy. - Maintenance therapy for opioid use disorder: supports long‑term abstinence and reduces relapse risk.

Libroxar may cause a range of adverse reactions. Patients should be monitored for any new or worsening symptoms.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Sweating: increased perspiration. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing requiring medical attention. - Severe hypotension: marked drop in blood pressure. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - QT interval prolongation: potential cardiac rhythm disturbance.

Before initiating Libroxar, clinicians should consider several safety measures.

- Assess patient history: evaluate prior opioid use, dependence severity, and comorbid conditions. - Monitor respiratory status: watch for signs of respiratory depression, especially during induction. - Avoid in acute severe asthma: risk of bronchospasm may be heightened. - Use caution in hepatic impairment: dose adjustments may be required. - Educate on sublingual administration: ensure tablet is placed under the tongue and not swallowed. - Store at below 25°C: keep in the original pack, protect from moisture.

Libroxar can interact with other medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Benzodiazepines: increased risk of profound sedation and respiratory depression. - Other opioids: additive opioid effects may lead to overdose. - Alcohol: potentiates central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise buprenorphine levels. - Antidepressants (SSRIs, SNRIs): can enhance serotonergic activity. - Antihypertensives (e.g., clonidine): may cause additive hypotensive effects.